Apollomics shares are trading lower after the company announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at ESMO 2023.
Portfolio Pulse from Benzinga Newsdesk
Apollomics has announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at ESMO 2023, causing its shares to trade lower.
October 23, 2023 | 3:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Apollomics shares are trading lower following the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial.
The presentation of the vebreltinib data from the KUNPENG trial seems to have negatively impacted investor sentiment, leading to a drop in Apollomics' share price. This suggests that the market may have had higher expectations for the trial results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100